What Happened to the Firewall?
Merck's obvious and exclusive success with Medco has other drug-company owned PBMs crying foul. But now a lawsuit against Medco questions the length to which the PBM will go to help its pharmaceutical parent. And it comes at a time when PBMs, in general, seem to be moving away from formulary policies that restrict patient choice.
You may also be interested in...
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.